Alere Inc. buy tamam
Start price
15.04.17
/
50%
€44.51
Target price
15.06.17
€46.00
Performance (%)
1.22%
End price
15.06.17
€45.05
Summary
This prediction ended on 15.06.17 with a price of €45.05. The BUY prediction by tamam finished with a performance of 1.22%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alere Inc. | - | - | - | - |
| iShares Core DAX® | 2.275% | 4.627% | 18.839% | 16.367% |
| iShares Nasdaq 100 | 6.015% | 2.007% | 23.636% | 35.232% |
| iShares Nikkei 225® | 4.456% | 3.598% | 12.437% | -0.660% |
| iShares S&P 500 | 4.061% | 2.876% | 23.447% | 38.511% |
Comments by tamam for this prediction
In the thread Alere Inc. diskutieren
Alera, the global leader in point of care diagnostics
Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology.
Abbott Laboratories (NYSE:ABT) agrees to aquire Alere (NYSE:ALR) for $51/share
(Laufzeit überschritten)